This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Ghanta, V. K. Articles by Hiramoto, R. N. Search for Related Content PubMed PubMed Citation Articles by Ghanta, V. K. Articles by Hiramoto, R. N.

cis-Dichlorodiammineplatinum(II) Chemotherapy in Experimental Murine Myeloma MOPC 104E¹

Departments of Microbiology [V. K. G., M. T. J., D. A. W., R. N. H.] and Medicine [J. R. D.], and Comprehensive Cancer Center [V. K. G., R. N. H., J. R. D.], University of Alabama in Birmingham, Birmingham, Alabama 35294

Data are presented indicating marked antineoplastic activity for cis-dichlorodiammineplatinum(II) in MOPC 104E myeloma. One-eighteenth of the dose that produced 100% cures can be combined with noncurative, low doses of cyclophosphamide and 1,3-bis(2-chloroethyl)-1-nitrosourea to produce antineoplastic activity of the same degree as that produced by much higher dose regimens which regularly produce cures. Since, in the past, results of therapeutic trials in plasma cell tumors in humans have paralleled results in this animal model, clinical trials of cis-dichlorodiammineplatinum in multiple myeloma appear warranted.

¹ This investigation was supported by USPHS Grant 5-R01-CA14125 from the NIH, National Cancer Institute, in part by NIH Grant LM00154 from the National Library of Medicine, and in part by USPHS Grant 3-R01-CA19657, from the NIH, National Cancer Institute.

² To whom requests for reprints should be addressed.

Received 9/24/76. Accepted 12/ 2/76.